菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

Discover how early-stage developability assessment supports modality-driven lead optimization with in silico analysis, high-throughput in vitro assays, and risk-mitigation insights

 

 

Early-stage biologics discovery often focuses on binding affinity, while other developability attributes that affect downstream success are sometimes overlooked. Incorporating early developability assessment can help identify and mitigate potential liabilities in the pipeline.

 

This webinar will introduce the Micro Developability platform, a high-throughput analytical suite designed to assess key developability attributes using minimal protein input. The platform evaluates PK (self-association, non-specific binding, FcRn affinity, and serum stability), biophysical properties, stability, and immunogenicity. Through modality-driven study design, real-world case studies, and data interpretation, you will learn how these assessments guide lead optimization, mitigate downstream risks, and facilitate smoother progression from research to development.

 

In this webinar, you will discover:

 

  • Recently updated, integrated early developability panel combining in silico modeling and in vitro assays
  • High-throughput, robust, and highly sensitive assays for PK and biophysical assessment
  • Advanced immunogenicity assays specifically developed for early-stage lead evaluation
  • Purpose-driven forced degradation studies designed to support risk mitigation and closed-loop decision making

 

 

Webinar Details

 

Date: Thursday, May 21, 2026

Time: 9:00 AM PT | 12:00 PM ET | 5:00 PM BST

 

Speaker:

 

 

 

Lei Guo, Ph.D.

Senior Director, CRO Services

Dr. Lei Guo leads the Protein Analytical Chemistry group in the CRO Services Department at WuXi Biologics. Her team specializes in comprehensive analytical testing of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and fusion proteins during drug discovery and optimization stages, employing Mass Spectrometry and physicochemical & biophysical analyses. With over 16 years of experience in bioanalysis, Dr. Guo has held diverse roles at Pfizer, Sanofi, and MSD, contributing to target identification, lead optimization, drug development, and CMC-stage analytical support.

Enter your information to register

 

 

 

 

 

 

Have specific questions about early-stage developability assessment?

Reach out to our experts!

Your Project. Our Expertise.